絞り込み

16599

広告

1144件中 41件~60件表示    検索結果をPubMedで見る PubMedで見る

Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models.

On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele specific manner dependent on the original EGFR activating mutation.

Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation.

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.

Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.

Afatinib-loaded Immunoliposomes Functionalized with Cetuximab: a Novel Strategy Targeting the Epidermal Growth Factor Receptor for Treatment of Non-small-cell Lung Cancer.

NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.

Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of afatinib.

Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas.

Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology.

Long-lasting response to afatinib that persisted after treatment discontinuation in a case of -mutated lung adenocarcinoma.

Diarrhea With HER2-Targeted Agents in Cancer Patients: A Systematic Review and Meta-Analysis.

Banxia Xiexin Decoction () Combined with Afatinib in Treatment of Advanced Gallbladder Cancer: Case Report and Literature Review.

The genomic imprint of cancer therapies helps timing the formation of metastases.

Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung.

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.

Modelling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります